Company Overview and News

 
Renegade Exploration revs up for major drilling program in premier gold country

2018-05-21 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) will get the drill bit spinning in early June targeting gold at its Yandal East project in the gold-rich Yandal Greenstone Belt of Western Australia.

 
Renegade Exploration leveraged to gold news flow from world-class Yandal Greenstone Belt

2018-05-10 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) is focused on finding another major gold project in the elephant country that is the Yandal Greenstone Belt near Wiluna in Western Australia’s North Eastern Goldfields.

 
Junior explorers raise $21m

2018-03-16 businessnews.com.au
Three local junior explorers have raised more than $21 million, with gold-focused Draig Resources tapping investors for $8 million, Triton Minerals receiving a $5.2 million boost and Eagle Mounting Mining raising $8 million via an initial public offering.

 
Draig, Triton raise $13m

2018-03-16 businessnews.com.au
Two local junior explorers have raised more than $13 million, with gold-focused Draig Resources tapping investors for $8 million to fund exploration at its Bellevue project north of Leinster.

 
Junior explorers raise $13m

2018-03-16 businessnews.com.au
Two local junior explorers have raised more than $13 million, with gold-focused Draig Resources tapping investors for $8 million to fund exploration at its Bellevue project north of Leinster.

 
Draig Resources attracts $8 million to fast-track Bellevue Gold Project

2018-03-16 proactiveinvestors.com.au
Draig Resources Ltd (ASX:DRG) has completed an oversubscribed share placement to institutional and sophisticated investors to raise $8 million at 20 cents per share.

 
Junior gold miners raise $12m

2017-11-30 businessnews.com.au
Junior miners Draig Resources and Capricorn Metals will tap investors in separate capital raisings as both companies advance their respective Western Australian gold projects.

 
Junior gold miners tap investors

2017-11-30 businessnews.com.au
Junior miners Draig Resources and Capricorn Metals will tap investors in separate capital raisings as both companies advance their respective Western Australian gold projects.

 
Junior explorers soar on drilling results

2017-11-20 businessnews.com.au
Shares in junior mining explorers Draig Resources and St George Mining have nearly doubled today after both companies announced positive drilling results.

 
Draig Resources nearly doubles in value on bonanza gold hit

2017-11-20 proactiveinvestors.com.au
Draig Resources Ltd (ASX:DRG) is among the top performing stocks on the ASX intra-day, with its shares leaping 95% to $0.235 with over 22 million changing hands.

 
Draig Resources aims to unlock potential of one of Australia’s historic high-grade gold mines

2017-11-19 proactiveinvestors.com.au
Draig Resources Ltd (ASX:DRG) recently delineated multiple high-grade gold lodes at the Bellevue Gold Project in Western Australia.

 
Venturex Resources tops ASX Most Traded, next door neighbour is De Grey Mining

2017-09-29 proactiveinvestors.com.au
Venturex Resources Ltd's (ASX:VRX) shares have jumped 19% to $0.019 in the first hour of trade, while also being the most active stock on the ASX with 44 million changing hands.

 
Draig Resources' shares trade at 12-month highs, calls halt for raising

2017-08-18 proactiveinvestors.com.au
Draig Resources Ltd's (ASX:DRG) shares are trading at 12-month highs at around $0.06, which is more than double their valuation at the start of 2017.

 
Parsons to lead Draig

2017-03-31 businessnews.com.au
Draig Resources has a new management team that includes former Gryphon Minerals managing director Stephen Parsons, who will focus on the company's recently acquired Bellevue gold project west of Laverton.

 
Draig Resources in an ASX trading halt

2017-03-29 proactiveinvestors.com.au
Draig Resources (ASX:DRG) has been granted a trading halt by the ASX, with its shares placed in pre-open.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...